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Claude Daubert, MD,§ on behalf of the REVERSE Study Group
Stockholm, Sweden; Columbus, Ohio; Charleston, South Carolina; and Rennes, France
Objectives The purpose of this study was to determine the effects of cardiac resynchronization therapy (CRT) with respect
to heart failure etiology among patients in the REVERSE (REsynchronization reVErses Remodeling in Systolic Left
vEntricular Dysfunction) study.
Background CRT improves outcomes in New York Heart Association functional class III/IV heart failure with wide QRS with a
more pronounced effect on left ventricular (LV) reverse remodeling in nonischemic patients.
Methods A total of 277 patients with nonischemic heart disease (IHD) and 333 with IHD etiology in New York Heart Asso-
ciation functional class I or II with QRS 120 ms and left ventricular ejection fraction 40% received a CRT
( implantable cardioverter-defibrillator) and were randomized to CRT-ON or CRT-OFF for 12 months. The
primary end point was the percentage of patients worsened by the HF clinical composite response, and
multiple prespecified secondary end points were evaluated regarding etiology using univariable and multi-
variable analysis.
Results At baseline, IHD patients were significantly older and had more comorbidities and less dyssynchrony than non-
IHD patients. In non-IHD patients, 10% worsened in CRT-ON compared with 19% in CRT-OFF (p  0.01). In IHD
patients, 20% worsened in the CRT-ON compared with 24% in the CRT-OFF group (p  0.10). Non-IHD patients
assigned to CRT-ON improved more in left ventricular end-systolic volume index than IHD patients. Randomiza-
tion to CRT, left bundle branch block, and wider QRS duration independently predicted response to both end
points, whereas non-IHD etiology was an independent predictor only for left ventricular end-systolic volume index.
Conclusions This substudy of REVERSE shows that CRT reverses left ventricular remodeling with a more extensive effect on
nonischemic patients. Etiology was, however, not an independent predictor of clinical response. (REsynchronization
reVErses Remodeling in Systolic Left vEntricular Dysfunction [REVERSE]; NCT00271154) (J Am Coll Cardiol
2010;56:1826–31) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.055f
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oms, heart failure (HF) morbidity and mortality in New
ork Heart Association (NYHA) functional class III or IV
atients with left ventricular (LV) dysfunction, and QRS
rolongation (1–4). CRT also progressively improves LV
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ion reVErses Remodeling in Systolic Left vEntricular
ysfunction) study (7). The overall results confirm that
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November 23, 2010:1826–31 Effect of Etiology on CRT in Mild Heart FailureRT induces reverse LV remodeling and delays the time to
rst HF-related hospitalization over 12 months with further
mprovement over time (8). It has been suggested that the
esponse by CRT treatment is affected by etiology, in
articular regarding reverse remodeling (9–11). The aim of
his report was to study the REVERSE results in relation to
onischemic compared with ischemic HF etiology.
ethods
atient population. Eligible patients had American Col-
ege of Cardiology/American Heart Association stage C (7),
YHA functional class I or II HF with QRS duration
120 ms, left ventricular ejection fraction (LVEF) 40%,
nd LV end-diastolic diameter 55 mm. Ischemic heart
isease (IHD) was defined as a history of myocardial
nfarction or coronary revascularization and/or evidence of
- or 3-vessel disease by coronary angiography and non-
HD as the absence of these criteria.
tudy design, procedures, and end points. Patients were
ssessed at baseline, underwent implantation, and randomly
ssigned to active CRT (CRT-ON) or to control (CRT-
FF)  implantable cardioverter-defibrillator and evalu-
ted at 1, 3, 6, and 12 months in a double-blind fashion (7).
he primary end point was the percentage of patients
orsened by the HF clinical composite response (7). Left
entricular end-systolic volume index (LVESVi) was the
rospectively powered secondary end point.
tatistical methods. All results were analyzed according to
he intention-to-treat principle. All p values reported are
ominal, and all statistical tests are 2 sided. Kaplan-Meier
nalysis was used to analyze time to first HF hospitalization.
he log-rank test was used to assess significance. Student’s
test was used for comparisons of means, and the Fisher
xact test was used to compare proportions. Randomization,
tiology, and their interaction were examined for secondary
nd points using analysis of variance methods. A logistic
egression model was used for multivariable analysis of the
linical composite response at 12 months and a regression
odel for change in the LVESVi from baseline to 12
onths. Backward stepwise elimination was used to reduce
he model to factors with p values 0.05. Baseline factors
onsidered were randomization group, etiology, age, sex,
YHA functional class, systolic blood pressure, LVEF,
VESVi, left bundle branch block (LBBB), baseline QRS
uration, at least 50% target dose of beta-blockers, glomer-
lar filtration rate, diabetes, history of hypertension, coro-
ary artery bypass graft, and previous percutaneous coronary
ntervention.
esults
tudy population. Baseline characteristics (Table 1) show
hat the 277 IHD patients were significantly older and had
ore comorbidities than the 333 non-IHD patients. LVEF
as significantly higher in IHD compared with non-IHD
atients. Non-IHD patients more often were female, less often weceived a concomitant implant-
ble cardioverter-defibrillator, had
arger LV dimensions, wider QRS
idth, and longer intraventricular
echanical delay duration (Table 1).
BBB was significantly more fre-
uent in non-IHD patients. IHD
atients less often received at
east 50% of the target dose of
eta-blockers.
ffects on primary and secondary
nd points at 12 months. Com-
ared with control, CRT signifi-
antly reduced the percentage of
atients worsened by the HF com-
osite response in non-IHD pa-
ients but not in IHD patients
Fig. 1). Compared with CRT-
FF, the LVESVi significantly improved in both groups at
2 months, with a greater improvement in non-IHD
RT-ON patients (29.5  30.6 ml/m2 vs. 7.0  25.5
l/m2, p  0.0001) compared with IHD CRT-ON pa-
ients (9.5  24.1 ml/m2 vs. 3.1  20.6 ml/m2, p 
.0001) (Fig. 2). In an analysis of variance model, random-
zation (p  0.0001), etiology (p  0.0001), and their
nteraction (p  0.045) were all predictors of LVESVi
hange over 12 months (Table 2). In the non-IHD group,
VEF significantly improved by 7.5  9.3% in the
RT-ON group after 12 months compared with 1.4 
.2% in CRT-OFF group (p 0.0001). In the IHD group,
t improved by 2.2  8.5% in CRT-ON compared with
.3 6.0% in CRT-OFF (p 0.03). The change in LVEF
as associated with randomization (p  0.0001), etiology
p 0.0001) and the interaction between the 2 (p 0.008).
In non-IHD patients, CRT significantly improved the
innesota Living With Heart Failure Quality of Life
uestionnaire score, whereas the 6-min walk distance was
naffected (Table 2). Among baseline NYHA functional
lass II patients, 43% of CRT-ON non-IHD patients
mproved to NYHA functional class I compared with 32%
f CRT-OFF patients (p  0.09). In NYHA functional
lass II IHD patients, 35% of CRT-ON patients improved
o NYHA functional class I compared with 20% of CRT-
FF patients (p  0.02). In a logistic regression model, the
nteraction term of randomization and NYHA functional
lass was not significant (p  0.52).
F hospitalizations. The time to first HF hospitalization
s shown in Figure 3. The overall morbidity in both
andomization arms was larger in ischemic patients than in
onischemic patients, reflecting the older age and the
reater baseline morbidity in the IHD patients. Non-IHD
atients had a 5.3% HF hospitalization rate over 12 months
n the CRT-OFF group compared with 2.9% in the
RT-ON group. The corresponding rates for IHD patients
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
HF  heart failure
IHD  ischemic heart
disease
LBBB  left bundle branch
block
LV  left ventricular
LVEF  left ventricular
ejection fraction
LVESVi  left ventricular
end-systolic volume index
NYHA  New York Heart
Associationere 10.3% and 5.0%, respectively. The difference in time to
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ON in the IHD group was statistically significant (p 
.03), although in a proportional hazards model with HF
ospitalization as independent variable, randomization was
ignificant (p  0.03), but etiology (p  0.12) was not.
atient Characteristics inonischemic and I chemic PatientsTable 1 P ient Characteristic inNonischemic and Ischemic Patients
Nonischemic
(n  277)
Ischemic
(n  333) p Value
Age, yrs 57.6 11.1 66.6 9.0 0.0001
Men 67 88 0.0001
New York Heart Association functional
class II
86 80 0.07
Previous myocardial infarction 0 84 0.0001
Previous coronary artery bypass
grafting
0 52 0.0001
Previous percutaneous coronary
intervention
1 46 0.0001
Diabetes 13 30 0.0001
History of hypertension 44 58 0.001
Chronic obstructive pulmonary disease 7 13 0.01
Peripheral vascular disease 3 13 0.0001
Angiotensin-converting enzyme
inhibitor
83 75 0.02
Angiotensin-converting enzyme
inhibitor or angiotensin-receptor
blocker
98 96 0.18
Beta-adrenergic blocker 96 95 0.58
50% of target beta-adrenergic
blocker dose
69 53 0.0001
100% of target beta-adrenergic
blocker dose
44 28 0.0001
Diuretic 81 79 0.48
Left bundle branch block 88 68 0.0001
Right bundle branch block 5 15 0.0001
Intrinsic QRS duration, ms 157 21 150 22 0.0004
Interventricular mechanical delay, ms 46.8 35.7 22.7 38.3 0.0001
Left ventricular
Ejection fraction, % 26.1 6.7 27.6 6.5 0.006
End-diastolic diameter, cm 7.0 1.0 6.9 0.8 0.28
End-systolic diameter, cm 5.9 1.2 5.7 0.9 0.08
End-systolic volume, cm3 210 94 190 65 0.006
End-diastolic volume, cm3 279 108 261 78 0.02
Mass, g 267 87 274 66 0.40
Glomerular filtration rate, ml/min 95.5 35.7 77.9 28.4 0.0001
Heart rate, beats/min 68.4 10.4 66.4 10.5 0.02
Supine blood pressure, mm Hg
Systolic 123 17 126 20 0.07
Diastolic 73 11 72 11 0.27
Body weight, kg 85.0 19.5 86.6 16.9 0.28
Minnesota Living With Heart Failure
Quality of Life Questionnaire
score
29.0 20.4 26.4 20.8 0.14
Kansas City Cardiomyopathy
Quality of Life Questionnaire
summary score
70.4 19.9 74.6 20.0 0.02
6-min hall walk, m 420 122 374 128 0.0001
CRT-D implanted, % 79 86 0.02
alues are mean  SD or percentage of patients in corresponding group.
CRT-D  cardiac resynchronization therapy-defibrillator.here were 4 deaths in non-IHD patients (CRT-OFF,.1%; CRT-ON, 1.1%; p  0.61) and 8 deaths in IHD
atients (CRT-OFF, 3.0%; CRT-ON, 1.0%; p  0.45).
The results of models for independent predictors of both
linical composite response and change in LVESVi are
hown in Table 3. History of LBBB was a significant
redictor of response to both end points as was randomiza-
ion (to CRT) and baseline QRS duration (long rather than
hort). Age was an independent predictor only for clinical
esponse, and etiology was an independent predictor only
or LVESVi. Even when age was removed from the model,
tiology still was not a predictor of clinical composite
esponse (p  0.52). Interaction of randomization and
tiology with the other significant predictors was examined
y individually adding these terms into the models. No
nteraction terms were significant when added into the
linical composite response model; however, in the LVESVi
odel, all 4 predictors interacting with randomization were
ignificant, as well as etiology with LVEF and QRS
uration.
iscussion
he major finding of this substudy of REVERSE was that
he extent of reverse remodeling was greater in non-IHD
atients. Our findings concur with results from earlier CRT
tudies of NYHA functional class III/IV HF patients (5,6).
We previously reported a significant correlation between
lectrical and mechanical dyssynchrony and reverse remod-
ling in REVERSE (12). It is possible that the lesser degree
Figure 1 Distribution of the Primary End Point
Regarding Worsened, Unchanged, or Improved
The p values compare cardiac resynchronization therapy (CRT)-OFF and -ON
within non-ischemic heart disease (IHD) and IHD using the Fisher exact test.
The analysis of effects is from a cumulative logistic regression with clinical
composite response as the dependent variable in the model. Odds ratios are
cumulative over improved, unchanged, and worsened. The interaction term of
randomization*etiology was not significant (p  0.44), so it is not included in
the analysis of effects. Rand  randomization group (CRT-OFF or -ON).
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November 23, 2010:1826–31 Effect of Etiology on CRT in Mild Heart Failuref dyssynchrony in IHD patients partly explained the less
xtent of reverse remodeling by CRT. Indeed, LBBB and
RS duration were multivariate predictors of reverse re-
odeling by CRT, but IHD etiology was not. It can also be
peculated that CRT is less effective when contractility is
mpaired by extensive myocardial scar tissue, even in the
resence of conduction delay. This could reflect the less
plasticity” of myocardial scar tissue to both dilate and
Figure 2 Reverse Remodeling Left Ventricular End-Systolic and
in Nonischemic and Ischemic Patients During CRT-ON
The p values compare change from baseline to 12 months between cardiac resync
Error bars represent 95% confidence intervals.
2-Month Results by Randomization in the Non-IHD and IHD GroupsTable 2 12-Month Results by Randomization in the Non-IHD an
Parameter
Non-IHD
CRT-OFF
(n  94)
CRT-ON
(n  183) p Value*
CRT-
(n 
LVESVi 7.0 25.5 29.5 30.6 0.0001 3.1
LVEDVi 8.2 29.4 30.3 32.3 0.0001 4.1
LVEF 1.4 7.2 7.5 9.3 0.0001 0.3
IVMD 2.2 32.2 16.0 42.1 0.0009 2.1
6-min hall walk 20 108 20 99 0.99 17
MN LWHF 6.6 14.3 10.9 17.5 0.04 6.7
KC QoL 9.1 14.9 11.0 18.2 0.43 8.0
p value comparing CRT-ON and -OFF within the etiology subgroup. The final 3 columns are p values
he parameter as the dependent variable.
ANOVA analysis of variance; CRT cardiac resynchronization therapy; IHD ischemic heart duestionnaire (higher score is better); LVESVi  left ventricular end-systolic volume index; MN LWHF  M
andomization.hrink and confirms previous CRT study results in NYHA
unctional class III/IV patients (9–11). A further reason
ould be that IHD patients in REVERSE were older and
ad more comorbidities. When these factors were assessed
n a logistic regression model, LBBB, longer baseline QRS,
nd randomization to CRT were the only independent
redictors of response in the primary end point, but HF
tiology was not, indicating that clinical benefits of CRT
Diastolic Volume Index
-OFF
ation therapy (CRT)-ON and -OFF (2-sample t test).
Their Interaction by Regression ModelGroups and Their Interaction by Regression Model
IHD
ANOVA p Values
CRT-ON
(n  236) p Value* Rand Etiology Interaction
9.5 24.1 0.0001 0.0001 0.0001 0.045
10.6 29.5 0.0001 0.0001 0.0001 0.19
2.4 8.5 0.03 0.0001 0.0001 0.008
10.4 43.5 0.13 0.001 0.87 0.23
6 105 0.40 0.56 0.36 0.55
6.5 16.6 0.92 0.18 0.16 0.14
7.0 17.3 0.67 0.79 0.12 0.40
domization, etiology, and the interaction randomizationetiology terms in a regression model with
; IVMD intraventricular mechanical delay; KC QoL Kansas City Cardiomyopathy Quality of LifeEnd-
and
hronizandd IHD
OFF
97)
20.6
25.5
6.0
35.2
103
17.4
17.2
for ran
isease
innesota Living With Heart Failure Quality of Life Questionnaire (lower score is better); Rand 
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Effect of Etiology on CRT in Mild Heart Failure November 23, 2010:1826–31ccurred irrespective of age and etiology. These results agree
ith those of the CARE-HF (CArdiac REsynchronization
n Heart Failure) study in which the clinical benefit was
imilar in non-IHD and IHD patients despite less reverse
V remodeling, more advanced age, and more comorbidi-
ies in IHD patients. As in REVERSE, etiology was not an
ndependent predictor of response to CRT by multivariable
nalysis (10). Our study suggests that LBBB and baseline
RS duration are important determinants of response to
RT in mild HF beyond reverse remodeling.
Figure 3 Time to First Heart Failure–Related Hospitalization in
During CRT-ON and -OFF, Respectively
CRT  cardiac resynchronization therapy; HF  heart failure; HR  hazard ratio.
ssessment of Independent Predictors of ResponseTable 3 Assessment of Independent Predictors of Response
Clinical Composite Respons
Odds Ratio 95% CI
Randomization (CRT-ON) 0.56 0.40 to 0.79
Age, yrs 0.98 0.97 to 1.00
QRS duration, ms 1.01 1.00 to 1.02
History of LBBB 0.66 0.45 to 0.97
Etiology (nonischemic)
Sex
NYHA functional class II 0.31 0.21 to 0.48
Systolic blood pressure, mm Hg
LVEF
LVESVi, ml/m2 0.995 0.990 to 0.999
Beta-blocker 50% target dose
Glomerular filtration rate, ml/min
Diabetes
History of hypertension
Coronary artery bypass graft
Previous PCI
he p values are for factor effect in a multivariable logistic regressionmodel for clinical composite s
or dichotomous variables, the state more likely to see improvement is indicated.
CI  confidence interval; LBBB  left bundle branch block; LVEF  left ventricular ejection fraction; NYThe treatment goal in mild HF strives to keep patients as
ong as possible from worsening. REVERSE was the first
andomized, controlled CRT study with this perspective but
as not designed to study morbidity and mortality.
ADIT-CRT (The Multicenter Automatic Defibrillator
mplantation Trial–Cardiac Resynchronization Therapy)
13) found a significant reduction in HF events predomi-
antly by reduction of HF hospitalization independent of
tiology or age but restricted to patients with baseline QRS
uration of at least 150 ms. The results from MADIT-CRT
chemic and Ischemic Patients
LVESVi
Value Regression Coefficient 95% CI p Value
0.0008 18.4 13.8 to 23.0 0.0001
0.03
0.05 0.14 0.24 to0.03 0.01
0.03 6.7 12.1 to0.3 0.01
12.7 8.2 to 17.3 0.0001
— —
0.0001
— —
0.99 0.66 to 1.33 0.0001
0.03
— —
— —
— —
— —
— —
— —
12months and amultivariable regressionmodel for change in LVESVi from baseline to 12months.Nonise
p

core atHA  New York Heart Association; other abbreviations as in Table 2.
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November 23, 2010:1826–31 Effect of Etiology on CRT in Mild Heart Failurere very concurrent with the REVERSE results and most
ikely over time will translate into a wider use of CRT in
ildly symptomatic patients to prevent disease progression.
tudy limitations. The multivariable models included 16
erms that were believed to be potentially predictive of
esults. Inclusion of this many terms may result in overfit-
ing of the models.
onclusions
his substudy of REVERSE shows that CRT reverses LV
emodeling with a more extensive effect in non-IHD
atients. Etiology was, however, not an independent pre-
ictor of clinical response. Longer observation periods and
arger patient groups are needed to firmly determine the
nfluence of etiology on CRT response.
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